EP1534286B1

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Abstract

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

EP1534286B1, drawing sheet 1
Sheet 1 of 653

Term

Term ended

Expired 29 July 2023, 3.2 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

45 claims: 3 independent, 42 dependent

  1. 1
    A 2,4-pyrimidinediamine compound for use in the treatment of an autoimmune disease other than ulcerative colitis, Crohn's disease, inflammatory bowel, and idiopathic inflammatory bowel disease, wherein the 2,4-pyrimidinediamine compound is:a compound of structural formula (I): or a salt, hydrate, solvate and/or an N-oxide thereof, wherein: L 1 and L 2 are each, a direct bond;R 2 is selected from the group consisting of phenyl mono substituted at the 3- or 5-position with an R 8 group, phenyl di- or tri-substituted with one or more of the same or different R 8 groups and an optionally substituted heteroaryl as defined below;R 4 is selected from the group consisting of phenyl substituted with one or more of the same or different R 8 groups and an optionally substituted heteroaryl as defined below;wherein, for R 2 and R 4 , each of said optionally substituted heteroaryl, independent of one another, is selected from the group consisting of: and wherein: p is an integer from one to three;each --- independently represents a single bond or a double bond;R 35 is hydrogen or R 8 ;X is selected from the group consisting of CH, N and N-O;each Y is independently selected from the group consisting of O, S and NH;each Y 1 is independently selected from the group consisting of O, S, SO, SO 2 , SONR 36 , NH and NR 37 ;each Y 2 is independently selected from the group consisting of CH, CH 2 , O, S, N, NH and NR 37 ;R 36 is hydrogen or alkyl;R 37 is selected from the group consisting of hydrogen and a progroup selected from the group consisting of aryl, arylalkyl, heteroaryl, R a , R b , -CR a R b -O-C(O)R 8 , -CR a R b -O-PO(OR 8 ) 2 , -CH 2 -O-PO(OR 8 ) 2 , -CH 2 -PO(OR 8 ) 2 , -C(O)-CR a R b -N(CH3) 2 , -CR a R b -O-C(O)-CR a R b -N(CH 3 ) 2 , -C(O)R 8 , -C(O)CF 3 and -C(O)-NR 8 -C(O)R 8 ;R 38 is selected from the group consisting of alkyl and aryl;A is selected from the group consisting of O, NH and NR 38 ;R 9 , R 10 , R 11 and R 12 are each, independently of one another, selected from the group consisting of alkyl, alkoxy, halogen, haloalkoxy, aminoalkyl and hydroxyalkyl, or, alternatively, R 9 and R 10 and/or R 11 and R 12 are taken together to form a ketal;each Z is selected from the group consisting of hydroxyl, alkoxy, aryloxy, ester, and carbamate;Q is selected from the group consisting of -OH, -OR 8 , -NR c R c , -NR 39 -CHR 40 -R b , -NR 39 -(CH 2 ) m -R b and -NR 39 -C(O)-CHR 40 -NR c R c ;R 39 and R 40 are each, independently of one another, selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, arylalkyl and NHR 8 ;R 5 is selected from the group consisting of -CN, -NC, , fluoro, (C1-C3) haloalkyl, (C1-C3) perhaloalkyl, (C1-C3) haloalkoxy, (C1-C3) perhaloalkoxy, -C(O)R a , -C(O)OR a , -C(O)CF 3 and -C(O)OCF 3 ;R 6 is hydrogen;R 8 is selected from the group consisting of R e , R b , R e substituted with one or more of the same or different R a or R b , -OR a substituted with one or more of the same or different R a or R b , -B(OR a ) 2 , -B(NR c R c ) 2 , -(CH 2 ) m -R b , -(CHR a ) m -R b , -O-(CH 2 ) m -R b , -S-(CH 2 ) m -R b , -O-CHR a R b , -O-CR a (R b ) 2 , -O-(CHR a ) m -R b , -O- (CH 2 ) m -CH[(CH 2 ) m R b ]R b , -S-(CHR a ) m -R b , -C(O)NH-(CH 2 ) m -R b , -C(O)NH-(CHR a ) m -R b , -O-(CH 2 ) m -C(O)NH-(CH 2 ) m -R b , -S-(CH 2 ) m -C(O)NH-(CH 2 ) m -R b , -O-(CHR a ) m -C(O)NH-(CHR a ) m -R b , -S-(CHR 3 ) m -C(O)NH-(CHR a ) m -R b , -NH-(CH 2 ) m -R b , -NH-(CHR a ) m -R b , -N[(CH 2 ) m R b ] 2 , -NH-C(O)-NH-(CH 2 ) m -R b , -NH-C(O)-(CH 2 ) m -CHR b R b and -NH-(CH 2 ) m -C(O)-NH-(CH 2 ) m -R b ;each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, (C6-C16) arylalkyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;each R b is a suitable group independently selected from the group consisting of =O -OR d , (C1-C3) haloalkyloxy, =S, -SR d , =NR d , =NOR d , -NR c R c , halogen, -CF 3 , -CN, -NC, -OCN, -SCN, -NO, -NO 2 =N 2 , -N 3 , -S(O)R d , -S(O) 2 R d , -S(O) 2 OR d , -S(O)NR c R c , -S(O) 2 NR c R c , -OS(O)R d , -OS(O) 2 R d , -OS(O) 2 OR d , -OS(O) 2 NR c R c , -C(O)R d , -C(O)OR d , -C(O)NR c R c , -C(NH)NR c R c , -C(NR a )NR c R c , -C(NOH)R a , -C(NOH)NR c R c , -OC(O)R d , -OC(O)OR d , -OC(O)NR c R c , -OC(NH)NR c R c , -OC(NR a )NR c R c , -[NHC(O)] n R d , -[NR 3 C(O)] n R d , -[NHC(O)] n OR d , -[NR a C(O)] n OR d , -[NHC(O)] n NR c R c , -[NR a C(O)] n NR c R c , -[NHC(NH)] n NR c R c and -[NR a C(NR a )] n NR c R c ;each R c is independently R a , or, alternatively, two R c are taken together with the nitrogen atom to which they are bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;each R d is independently an R a ;each R e is independently selected from the group consisting of (C1-C6) alkyl, (C3-C8) cycloalkyl,-(C4-C11) cycloalkylalkyl, (C5-C10) aryl, (C6-C16) arylalkyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;each m is independently an integer from 1 to 3;and each n is independently an integer from 0 to 3;or the 2,4-pyrimidinediamine compound is a compound selected from the group consisting of 7.4.214 through 7.4.244, 7.4.250 through 7.4.252, 7.4.256 through 7.4.258, 7.4.262 through 7.4.269, 7.4.272 through 7.4.276, 7.4.278 through 7.4.280, 7.4.283 through 7.4.289, 7.4.296, 7.4.298 through 7.4.302, 7.4.304, 7.4.305, 7.4.308 through 7.4.313, 7.4.315, 7.4.317, and 7.4.318;with the provisos that in formula (I): (1) when R 2 is a substituted phenyl, then R 5 is other than cyano or -C(O)NHR, where R is hydrogen or (C1-C6) alkyl;(2) when R 2 and R 4 are each independently a substituted or unsubstituted indole, then the R 2 and R 4 are attached to the remainder of the molecule via a ring carbon atom;and (3) the compound is not
  2. 38
    The compound of any one of claims 1-37 which is for use in the form of a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, diluent or excipient.
  3. 39
    The compound of any one of Claims 1-37 in which the autoimmune disease is selected from the group consisting of autoimmune diseases that are frequently designated as single organ or single cell-type autoimmune disorders and autoimmune diseases that are frequently designated as involving systemic autoimmune disorder.